It was October 2007 when Ann Havelock, who was 67-years-old at the time, started feeling that something was wrong with her body. What began with frigid hands, rapidly evolved to excruciating pain. But it took a year and a half and visits to half a dozen physicians to confirm her diagnosis. She…
Therapeutic plasma exchange (TPE) is a novel method for patients with scleroderma that may revolutionize the treatment of the disease and is considered a new hope for patients. The technique was recently presented at the American Society for Apheresis (ASFA) 2016 Annual Meeting in a presentation titled “Therapeutic Plasma Exchange…
The Scleroderma Foundation has made an appeal for scleroderma patients to participate in a research study focused on assessing an internet self-management program. The request was made by the organization on their Facebook page while the trial will be conducted by the University of Michigan, with the collaboration of…
Cumberland Pharmaceuticals, Inc., recently announced the addition to its drug pipeline of Vasculan (ifetroban), an oral capsule that soon will enter clinical testing as a treatment of systemic sclerosis (SSc), or scleroderma. Vasculan is being evaluated for safety and efficacy in a randomized, double-blind and placebo-controlled Phase 2 clinical study in people with…
The Phase 3 STAR clinical trial from Cytori Therapeutics recently enrolled and treated its 60th patient — 75 percent of target patient enrollment. The FDA-approved Phase 3 STAR study is assessing the one-year safety and efficacy of the Celution Therapy ECCS-50 in the processing of an autologous graft consisting of adipose (fat) derived…
The U.S. Food and Drug Administration (FDA) has designated a potential gene therapy for localized scleroderma, FCX-013 by Fibrocell Science, an orphan drug to help advance its development and testing. Fibroblasts, the basis of Fibrocell’s personalized cell and gene therapy platform, are the most common cell in skin and connective tissue, and responsible…
The U.S. Food and Drug Administration (FDA) approved Corbus Pharmaceuticals’ 12-month, open-label extension study of its ongoing Phase 2 clinical trial of Resunab for the treatment of diffuse cutaneous systemic sclerosis (scleroderma). The extension study aims to offer all participants the option of receiving Resunab after they complete the 84-day, Phase 2,…
Cytori Therapeutics has enrolled and treated its 40th patient with scleroderma in the Phase 3 STAR clinical trial for ECCS-50, marking 50 percent of target enrollment. The company also said a data monitoring committee has reviewed the safety results from the first 20 patients treated in the trial and has recommended it…
In July 2014, Edward Harris launched a website called the Scleroderma Education Project, where he writes and publishes articles providing comprehensive, unbiased, and research-based information about scleroderma. His articles are crafted to an audiences’ varied concerns — including a March 8 post on organ involvement in the disease — and…
Canada-based ProMetic Life Sciences, a global biopharma, recently announced it will launch a double-blind, placebo-controlled Phase 2 clinical trial in patients with scleroderma to evaluate its lead product PBI-4050. Drug candidate PBI-4050, taken orally, has confirmed safety and efficacy profiles through a series of in vivo studies in fibrosis. Fibrosis…
Get regular updates to your inbox.